Cytori updates on UI research using its Celution

San Diego, USA-headquartered Cytori Therapeutics says that the first subject has been enrolled in an investigator-initiated safety and  feasibility study using adipose-derived stem and regenerative cells to  treat stress urinary incontinence. The 10-patient study is being  conducted independently by Nagoya University Hospital in Japan. Cytori's  Celution 800 System is being used to process and extract the  patients'own adipose tissue-derived stem and regenerative cells at the  time of surgery.

"The Celution System is uniquely able to provide real-time access to  clinical-grade stem and regenerative cells to meet the growing demand  Cytori is seeing from physicians seeking regenerative medicine-based  treatments," said Seijiro Shirahama, president, Cytori Asia Pacific. "As  a result, hospitals are increasingly interested in a Celution purchase  to fill this need in the marketplace. This demand is partially  reflected in the seven investigator-initiated clinical studies taking  place in Japan which use the Celution System," he added.

As part of the study, stem cells were injected intra-muscularly into the  sphincter as well as in combination with a measured volume of the  patient's own fat tissue to create a bulking agent to support the  urethra. The study will evaluate safety, functional endpoints including  intraurethral pressure and leak point pressure, as well as subjective  assessments of patient and physician satisfaction, the firm said.